These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
562 related articles for article (PubMed ID: 31704217)
21. In vitro activity of imipenem-relebactam against various resistance phenotypes/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016-2019. Walkty A; Karlowsky JA; Baxter MR; Adam HJ; Golden A; Lagace-Wiens P; Zhanel GG; Diagn Microbiol Infect Dis; 2021 Sep; 101(1):115418. PubMed ID: 34102373 [TBL] [Abstract][Full Text] [Related]
22. Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020. García-Fernández S; Calvo J; Cercenado E; Suárez-Barrenechea AI; Fernández-Billón M; Castillo FJ; Gálvez-Benítez L; Tubau F; Figueroa Cerón RE; Hernández-Cabezas A; González Romo F; Fariñas MC; Gómez M; Díaz-Regañón J; Cantón R Rev Esp Quimioter; 2023 Jun; 36(3):302-309. PubMed ID: 36951688 [TBL] [Abstract][Full Text] [Related]
23. In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies). Hernández-García M; García-Castillo M; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Cruz H; Chaves C; Bou G; Cercenado E; Delgado-Valverde M; Oliver A; Pitart C; Rodríguez-Lozano J; Tormo N; Díaz-Regañón J; Pássaro L; Duarte J; Cantón R; J Antimicrob Chemother; 2022 Oct; 77(11):3163-3172. PubMed ID: 36059128 [TBL] [Abstract][Full Text] [Related]
29. Resistance Rates of Intra-Abdominal Isolates from Intensive Care Units and Non-Intensive Care Units in the United States: The Study for Monitoring Antimicrobial Resistance Trends 2010-2012. Hackel MA; Badal RE; Bouchillon SK; Biedenbach DJ; Hoban DJ Surg Infect (Larchmt); 2015 Jun; 16(3):298-304. PubMed ID: 25894976 [TBL] [Abstract][Full Text] [Related]
30. Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination. Mansour H; Ouweini AEL; Chahine EB; Karaoui LR Am J Health Syst Pharm; 2021 Mar; 78(8):674-683. PubMed ID: 33580649 [TBL] [Abstract][Full Text] [Related]
31. Activity of imipenem/relebactam against carbapenemase-producing Enterobacteriaceae with high colistin resistance. Carpenter J; Neidig N; Campbell A; Thornsberry T; Truex T; Fortney T; Zhang Y; Bush K J Antimicrob Chemother; 2019 Nov; 74(11):3260-3263. PubMed ID: 31430370 [TBL] [Abstract][Full Text] [Related]
32. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme. Stone GG; Newell P; Gasink LB; Broadhurst H; Wardman A; Yates K; Chen Z; Song J; Chow JW J Antimicrob Chemother; 2018 Sep; 73(9):2519-2523. PubMed ID: 29912399 [TBL] [Abstract][Full Text] [Related]
33. Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections. Smith JR; Rybak JM; Claeys KC Pharmacotherapy; 2020 Apr; 40(4):343-356. PubMed ID: 32060929 [TBL] [Abstract][Full Text] [Related]
34. Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015. Karlowsky JA; Hoban DJ; Hackel MA; Lob SH; Sahm DF J Med Microbiol; 2017 Jan; 66(1):61-69. PubMed ID: 28051952 [TBL] [Abstract][Full Text] [Related]
35. Activity of imipenem/relebactam and comparators against gram-negative pathogens from patients with bloodstream infections in the United States and Canada - SMART 2018-2019. Lob SH; Hackel MA; Young K; Motyl MR; Sahm DF Diagn Microbiol Infect Dis; 2021 Aug; 100(4):115421. PubMed ID: 34082265 [TBL] [Abstract][Full Text] [Related]
36. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy-SMART 2017-2021. Karlowsky JA; Lob SH; Hawser SP; Kothari N; Siddiqui F; Alekseeva I; DeRyke CA; Young K; Motyl MR; Sahm DF Eur J Clin Microbiol Infect Dis; 2024 Jul; 43(7):1343-1348. PubMed ID: 38775873 [TBL] [Abstract][Full Text] [Related]
37. Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections. Alonso-García I; Vázquez-Ucha JC; Lasarte-Monterrubio C; González-Mayo E; Lada-Salvador P; Vela-Fernández R; Aja-Macaya P; Guijarro-Sánchez P; Rumbo-Feal S; Muíño-Andrade M; Fernández-González A; Martínez-Guitián M; Beceiro A; Rodríguez-Iglesias M; Oliver A; Arca-Suárez J; Galán-Sánchez F; Bou G J Antimicrob Chemother; 2023 May; 78(5):1195-1200. PubMed ID: 36918743 [TBL] [Abstract][Full Text] [Related]
38. In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae. Tselepis L; Langley GW; Aboklaish AF; Widlake E; Jackson DE; Walsh TR; Schofield CJ; Brem J; Tyrrell JM Int J Antimicrob Agents; 2020 Jul; 56(1):105925. PubMed ID: 32084512 [TBL] [Abstract][Full Text] [Related]